WELLESLEY HILLS, Mass., May 8 /PRNewswire-FirstCall/ -- MacroChem , a specialty pharmaceutical company, will be presenting at the Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco on Tuesday, May 15th at 3:15 PM CEST (9:15 EST). Robert DeLuccia, President & Chief Executive Officer, will be providing an update on the Company's developments and business strategy.
The Conference will include presentations by over 200 companies, as well as experts from the medical, scientific and investment communities. Mr. DeLuccia will be available to meet one-on-one with investors throughout the Conference.
A live audio webcast of this presentation can be accessed via: http://www.wsw.com/webcast/rrshq11/mchm. Information about MacroChem and an audio replay of the presentation will also be available for 90 days after the conference.
About Rodman & Renshaw
Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of proprietary product candidates is based on our drug delivery technologies: SEPA(R), MacroDerm(TM) and DermaPass(TM). Our lead product candidate is EcoNail(TM), a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. In addition to EcoNail and Opterone, our pipeline of early-stage product candidates is based on our SEPA, MacroDerm and DermaPass drug delivery technologies. For more information visit our website, http://www.macrochem.com.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com .
Contact: MacroChem Corp.: Bernard Patriacca - VP/CFO (781) 489-7310 Investor Relations: The Investor Relations Group, Inc. Jordan Silverstein/Christine Berni (212) 825-3210
MacroChem CorporationCONTACT: MacroChem Corp.: Bernard Patriacca, VP-CFO of MacroChemCorporation, +1-781-489-7310; or Investor Relations: Jordan Silverstein orChristine Berni of The Investor Relations Group, Inc. for MacroChemCorporation, +1-212-825-3210
